{"id":"bazedoxifene-acetate-tse-424","safety":{"commonSideEffects":[{"rate":null,"effect":"Hot flashes"},{"rate":null,"effect":"Leg cramps"},{"rate":null,"effect":"Musculoskeletal pain"},{"rate":null,"effect":"Venous thromboembolism"}]},"_chembl":{"chemblId":"CHEMBL2106615","moleculeType":"Small molecule","molecularWeight":"530.67"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bazedoxifene binds to estrogen receptors with tissue-selective activity, promoting bone formation and favorable lipid profiles similar to estrogen while blocking estrogen signaling in reproductive tissues to avoid proliferative effects. This dual action makes it suitable for postmenopausal women seeking osteoporosis prevention without increased risk of endometrial or breast cancer.","oneSentence":"Bazedoxifene is a selective estrogen receptor modulator (SERM) that acts as an estrogen agonist in bone and lipid metabolism while functioning as an antagonist in breast and uterine tissue.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:03:38.950Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of postmenopausal osteoporosis"},{"name":"Treatment of postmenopausal osteoporosis"}]},"trialDetails":[{"nctId":"NCT04821375","phase":"EARLY_PHASE1","title":"Pilot Study of Bazedoxifene Plus Conjugated Estrogen on Imaging and Blood Biomarkers","status":"COMPLETED","sponsor":"Carol Fabian, MD","startDate":"2021-12-02","conditions":"Increased Risk for Development of Breast Cancer","enrollment":16},{"nctId":"NCT04821141","phase":"PHASE2","title":"Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Kansas Medical Center","startDate":"2021-12-14","conditions":"Risk Reduction, Breast Cancer","enrollment":120},{"nctId":"NCT04002934","phase":"PHASE2","title":"Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis","status":"COMPLETED","sponsor":"Riley Bove, MD","startDate":"2019-09-10","conditions":"Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting","enrollment":63},{"nctId":"NCT02274571","phase":"EARLY_PHASE1","title":"Raising Insulin Sensitivity in Post Menopause","status":"COMPLETED","sponsor":"Pennington Biomedical Research Center","startDate":"2015-09","conditions":"Menopause","enrollment":8},{"nctId":"NCT02694809","phase":"PHASE2","title":"The PROMISE Study: Duavee in Women With DCIS","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2017-01","conditions":"Ductal Breast Carcinoma In Situ, Postmenopausal","enrollment":142},{"nctId":"NCT04103476","phase":"PHASE2","title":"Advancing Postmenopausal Preventive Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southern California","startDate":"2021-04-13","conditions":"Atherosclerosis, Cognitive Decline","enrollment":385},{"nctId":"NCT04478305","phase":"PHASE1","title":"Affect of Duavive on Mood & Anxiety Symptoms","status":"RECRUITING","sponsor":"St. Joseph's Healthcare Hamilton","startDate":"2024-07-03","conditions":"Menopause, Depression, Anxiety, Sleep","enrollment":30},{"nctId":"NCT05059626","phase":"PHASE4","title":"Endometriosis and Microvascular Dysfunction; Simvastatin and Duavee","status":"RECRUITING","sponsor":"Penn State University","startDate":"2023-12-01","conditions":"Endometriosis","enrollment":28},{"nctId":"NCT05073237","phase":"PHASE2","title":"Effects of Novel Estrogens on Glucose and Lipids in Postmenopausal Prediabetic Women Veterans","status":"WITHDRAWN","sponsor":"VA Office of Research and Development","startDate":"2024-04-08","conditions":"Menopause, Prediabetes, Obesity","enrollment":""},{"nctId":"NCT01416194","phase":"","title":"Bazedoxifene Post Approval Safety Study (PASS) in the European Union (EU)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-07-25","conditions":"Osteoporosis, Postmenopausal","enrollment":10497},{"nctId":"NCT04113993","phase":"PHASE4","title":"Bazedoxifene -Treatment for Women With Schizophrenia","status":"UNKNOWN","sponsor":"The Alfred","startDate":"2019-10-07","conditions":"Schizophrenia, Schizophreniform Disorders, Schizo Affective Disorder","enrollment":160},{"nctId":"NCT02237079","phase":"PHASE4","title":"Bazedoxifene/Conjugated Estrogens (BZA/CE) Improvement of Metabolism (BIM)","status":"COMPLETED","sponsor":"Tulane University Health Sciences Center","startDate":"2014-12","conditions":"Obesity, Glucose Homeostasis, Postmenopausal Symptoms","enrollment":17},{"nctId":"NCT05366621","phase":"","title":"Post-fracture Medication and Mortality","status":"COMPLETED","sponsor":"National Cheng-Kung University Hospital","startDate":"2020-11-01","conditions":"Osteoporosis, Osteoporosis Fracture, Drug Therapy","enrollment":216155},{"nctId":"NCT02448771","phase":"PHASE1, PHASE2","title":"A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2015-07-09","conditions":"Breast Cancer Stage IV, Unresectable Locally Advanced Invasive Breast Cancer, Metastatic Invasive Breast Cancer","enrollment":36},{"nctId":"NCT03740009","phase":"PHASE4","title":"Effects of a Tissue Selective Estrogen Complex (TSEC) on Depression and the Neural Reward System in the Perimenopause\"","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2019-01-02","conditions":"Perimenopausal Disorder, Depression","enrollment":20},{"nctId":"NCT04036929","phase":"NA","title":"Can we Use Estrogen-containing Therapy to Improve Pain in Women After Menopause With Hand Osteoarthritis?","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2019-05-09","conditions":"Hand Osteoarthritis","enrollment":28},{"nctId":"NCT03981341","phase":"PHASE3","title":"Impact of Estrogen + Estradiol Receptor Alpha Modulator Therapy on Oxidative Stress in Post-menopausal Women With and Without Sleep Apnea","status":"UNKNOWN","sponsor":"Laval University","startDate":"2019-11-01","conditions":"Sleep Apnea, Post Menopausal, Oxidative Stress","enrollment":36},{"nctId":"NCT02729701","phase":"PHASE2","title":"Pilot Study of the Effect of Duavee® on Benign Breast Tissue Proliferation","status":"COMPLETED","sponsor":"University of Kansas Medical Center","startDate":"2016-05","conditions":"Breast Cancer","enrollment":28},{"nctId":"NCT04812808","phase":"NA","title":"Bazedoxifene as a Concomitant Treatment of Patients With Metastatic Pancreatic Adenocarcinoma","status":"UNKNOWN","sponsor":"Hôpital Fribourgeois","startDate":"2022-02-01","conditions":"Pancreas Cancer","enrollment":10},{"nctId":"NCT04379024","phase":"EARLY_PHASE1","title":"Pilot Study of Effects of Duavee® on Imaging and Blood Biomarkers In Women With Menopausal Symptoms","status":"TERMINATED","sponsor":"Carol Fabian, MD","startDate":"2020-06-01","conditions":"Focus of Study is Healthy Women at Risk for Breast Cancer","enrollment":11},{"nctId":"NCT02602704","phase":"PHASE4","title":"Effectiveness of Bazedoxifene for Prevention of Glucocorticoid-induced Bone Loss in RA Patients","status":"COMPLETED","sponsor":"Hanyang University","startDate":"2015-12-29","conditions":"Arthritis, Rheumatoid","enrollment":114},{"nctId":"NCT02710214","phase":"PHASE2","title":"A TSEC for Symptom Management in Menopausal Women With Multiple Sclerosis","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2016-02","conditions":"Menopause, Multiple Sclerosis","enrollment":24},{"nctId":"NCT01793142","phase":"","title":"Post Marketing Surveillance For General Drug Use To Assess the Safety And Efficacy Profile Of Viviant In Usual Practice","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-10-24","conditions":"Osteoporosis","enrollment":3430},{"nctId":"NCT01470326","phase":"","title":"Viviant 20mg Special Investigation (Regulatory Post Marketing Commitment Plan)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-11","conditions":"Osteoporosis","enrollment":3187},{"nctId":"NCT03475719","phase":"PHASE1","title":"A Clinical Trial to Evaluate the Safety and Pharmacokinetic","status":"UNKNOWN","sponsor":"Huons Co., Ltd.","startDate":"2018-01-11","conditions":"Osteoporosis, Postmenopausal","enrollment":52},{"nctId":"NCT03382314","phase":"PHASE1","title":"HDDO-1614 Bio Equivalence Study","status":"COMPLETED","sponsor":"Hyundai Pharmaceutical Co., LTD.","startDate":"2017-10-16","conditions":"Osteoporosis","enrollment":38},{"nctId":"NCT03234244","phase":"PHASE1","title":"HDDO-1614 Intervention Trial","status":"COMPLETED","sponsor":"Hyundai Pharmaceutical Co., LTD.","startDate":"2017-04-12","conditions":"Osteoporosis","enrollment":37},{"nctId":"NCT03321318","phase":"PHASE1","title":"AK-R215 Pharmacokinetic Study Phase I","status":"UNKNOWN","sponsor":"Alvogen Korea","startDate":"2017-07-13","conditions":"Healthy","enrollment":52},{"nctId":"NCT03005340","phase":"PHASE1","title":"A Phase 1 Drug Drug Interaction Clinical Trial of C1-R215 and C2-R215 in Healthy Male Volunteers","status":"UNKNOWN","sponsor":"Alvogen Korea","startDate":"2016-12","conditions":"Healthy","enrollment":24},{"nctId":"NCT01973738","phase":"","title":"Comparison Between Raloxifene and Bazedoxifene","status":"UNKNOWN","sponsor":"Toshihiko Kono","startDate":"2012-01","conditions":"Selective Estrogen Receptor Modulator","enrollment":300},{"nctId":"NCT02090400","phase":"PHASE4","title":"Switching From Oral Bisphosphonates to Bazedoxifene to Evaluate Effects on Bone Mineral Density in Postmenopausal Women","status":"COMPLETED","sponsor":"Instituto Palacios","startDate":"2013-05","conditions":"Osteoporosis, Postmenopausal","enrollment":110},{"nctId":"NCT00367536","phase":"PHASE1","title":"Study Evaluating Three Bazedoxifene/Conjugated Estrogens Combination Tablet Formulations Versus BZA Oral Solution","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2006-08","conditions":"Postmenopause","enrollment":24},{"nctId":"NCT02100553","phase":"PHASE1","title":"Study Evaluating Effects of Multiple-Dose Administration of Itraconazole on the Single Dose Pharmacokinetics of Conjugated Estrogens/Bazedoxifene in Non-Obese and Obese Postmenopausal Women","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-04","conditions":"Healthy","enrollment":24},{"nctId":"NCT00774267","phase":"","title":"Study Evaluating Changes In Mammographic Breast Density","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-01","conditions":"Osteoporosis","enrollment":507},{"nctId":"NCT00808132","phase":"PHASE3","title":"Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-01","conditions":"Menopause, Osteoporosis","enrollment":1886},{"nctId":"NCT00242710","phase":"PHASE3","title":"Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women","status":"COMPLETED","sponsor":"Pfizer","startDate":"2005-09","conditions":"Endometrial Hyperplasia, Osteoporosis","enrollment":1083},{"nctId":"NCT00205777","phase":"PHASE3","title":"Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal Women","status":"COMPLETED","sponsor":"Pfizer","startDate":"2001-12","conditions":"Osteoporosis","enrollment":7609},{"nctId":"NCT01634789","phase":"PHASE1","title":"A Pilot Bioavailability Study of 3 Test Tablet Formulations of Bazedoxifene Compared With A Reference Tablet Formulation of Bazedoxifene/Conjugated Estrogens in Healthy Postmenopausal Women","status":"TERMINATED","sponsor":"Pfizer","startDate":"2012-08","conditions":"Healthy","enrollment":2},{"nctId":"NCT00706225","phase":"PHASE1","title":"Study Evaluating Potential Drug Interaction Of Bazedoxifene & Premarin In Healthy Postmenopausal Women","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2008-06","conditions":"Postmenopause","enrollment":30},{"nctId":"NCT00847821","phase":"","title":"Observational Study Analyzing RNA Expression Of Endometrial Biopsy Samples From Placebo, Bazedoxifene/Conjugated Estrogens And Raloxifene","status":"TERMINATED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2009-05","conditions":"Postmenopause","enrollment":185},{"nctId":"NCT00418236","phase":"","title":"Effect of Bazedoxifene, Raloxifene, and Placebo on Breast Density","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2006-10","conditions":"Breast Cancer","enrollment":400},{"nctId":"NCT00481169","phase":"PHASE3","title":"Study Evaluating TSE-424/Placebo/Raloxifene in Preventing Osteoporosis in Postmenopausal Women","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2001-07","conditions":"Osteoporosis","enrollment":1742},{"nctId":"NCT00745173","phase":"PHASE1","title":"Study Evaluating Premarin and Bazedoxifene Potential Interaction","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2008-09","conditions":"Postmenopause","enrollment":30},{"nctId":"NCT00675688","phase":"PHASE3","title":"Study Evaluating Safety and Efficacy of Bazedoxifene/Conjugated Estrogens Combinations in Postmenopausal Women","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2002-04","conditions":"Endometrial Hyperplasia, Osteoporosis","enrollment":3544},{"nctId":"NCT00550433","phase":"PHASE1","title":"Study Evaluating Bazedoxifene/CE in Postmenopausal Women","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2007-09","conditions":"Postmenopause","enrollment":""},{"nctId":"NCT00238732","phase":"PHASE3","title":"Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Vasomotor Symptoms Associated With Menopause","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2005-10","conditions":"Vaginal Atrophy","enrollment":650},{"nctId":"NCT00464789","phase":"PHASE1","title":"Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Healthy Postmenopausal Women","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2007-03","conditions":"Menopause","enrollment":""},{"nctId":"NCT00234819","phase":"PHASE3","title":"Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Symptoms Associated With Menopause","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2005-10","conditions":"Vasomotor Symptoms Associated With Menopause","enrollment":325},{"nctId":"NCT00465075","phase":"PHASE1","title":"Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations in Fed and Fasting in Healthy, Postmenopausal Women","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2007-03","conditions":"Healthy","enrollment":24},{"nctId":"NCT00384072","phase":"PHASE3","title":"Study Evaluating the Safety and Efficacy of Bazedoxifene in Postmenopausal Asian Women","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2006-05","conditions":"Postmenopause, Osteoporosis","enrollment":500},{"nctId":"NCT00479778","phase":"PHASE1","title":"Study Of Pharmacokinetic (PK) Profile of Bazedoxifene (BZA) in 2 BZA/Conjugated Estrogen Forms","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2007-04","conditions":"Postmenopause","enrollment":72},{"nctId":"NCT00550303","phase":"PHASE1","title":"Study Comparing Formulations of Bazedoxifene/Conjugated Estrogens","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2007-10","conditions":"Healthy","enrollment":28},{"nctId":"NCT00238745","phase":"PHASE2","title":"Study Evaluating Bazedoxifene Dose-Response in Japanese Patients With Postmenopausal Osteoporosis.","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2003-08","conditions":"Postmenopausal Osteoporosis","enrollment":375},{"nctId":"NCT00396799","phase":"PHASE1","title":"Bioequivalence Study Of Bazedoxifene/Conjugated Estrogen Tablets In Postmenopausal Women","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2006-11","conditions":"Menopause","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Bazedoxifene Acetate (TSE-424)","genericName":"Bazedoxifene Acetate (TSE-424)","companyName":"Wyeth is now a wholly owned subsidiary of Pfizer","companyId":"wyeth-is-now-a-wholly-owned-subsidiary-of-pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bazedoxifene is a selective estrogen receptor modulator (SERM) that acts as an estrogen agonist in bone and lipid metabolism while functioning as an antagonist in breast and uterine tissue. Used for Prevention of postmenopausal osteoporosis, Treatment of postmenopausal osteoporosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}